Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Jorge Cortes, Alexander E Perl, Hartmut Döhner, Hagop Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu Estey, Stephen Strickland, Jessica K Altman, Claudia D Baldus, Alan Burnett, Alwin Krämer, Nigel Russell, Neil P Shah, Catherine C Smith, Eunice S Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark Levis

Open source

DOI: 10.1016/s1470-2045(18)30240-7
Published: 2018-07
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-18-30240-7,
  title = {Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial},
  author = {Jorge Cortes and Alexander E Perl and Hartmut Döhner and Hagop Kantarjian and Giovanni Martinelli and Tibor Kovacsovics and Philippe Rousselot and Björn Steffen and Hervé Dombret and Elihu Estey and Stephen Strickland and Jessica K Altman and Claudia D Baldus and Alan Burnett and Alwin Krämer and Nigel Russell and Neil P Shah and Catherine C Smith and Eunice S Wang and Norbert Ifrah and Guy Gammon and Denise Trone and Deborah Lazzaretto and Mark Levis},
  year = {2018},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(18)30240-7},
  url = {https://doi.org/10.1016/s1470-2045(18)30240-7}
}

RIS

TY  - JOUR
TI  - Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
AU  - Jorge Cortes
AU  - Alexander E Perl
AU  - Hartmut Döhner
AU  - Hagop Kantarjian
AU  - Giovanni Martinelli
AU  - Tibor Kovacsovics
AU  - Philippe Rousselot
AU  - Björn Steffen
AU  - Hervé Dombret
AU  - Elihu Estey
AU  - Stephen Strickland
AU  - Jessica K Altman
AU  - Claudia D Baldus
AU  - Alan Burnett
AU  - Alwin Krämer
AU  - Nigel Russell
AU  - Neil P Shah
AU  - Catherine C Smith
AU  - Eunice S Wang
AU  - Norbert Ifrah
AU  - Guy Gammon
AU  - Denise Trone
AU  - Deborah Lazzaretto
AU  - Mark Levis
PY  - 2018
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(18)30240-7
UR  - https://doi.org/10.1016/s1470-2045(18)30240-7
ER  -

APA

Cortes, J., Perl, A. E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., Strickland, S., Altman, J. K., Baldus, C. D., Burnett, A., Krämer, A., Russell, N., Shah, N. P., Smith, C. C., Wang, E. S., Ifrah, N., Gammon, G., Trone, D., Lazzaretto, D., & Levis, M. (2018). Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30240-7

Source records

crossref · retrieved 2026-09-26T10:13:18.212Z